Sucampo Appoints Cary Claiborne as CFO

Sucampo Pharmaceuticals, an international pharmaceutical company, has appointed Cary Claiborne as chief financial officer (CFO), reporting to Ryuji Ueno, MD, PhD, PhD, chairman and chief executive officer (CEO), and James Egan, chief operating officer (COO). Claiborne has been Sucampo’s interim CFO since March 2011.

Claiborne brings to Sucampo more than 25 years of financial expertise and senior leadership experience in both publicly traded and privately-held companies. Before his appointment in March 2011 as Sucampo’s interim CFO, Claiborne had been president and CEO of New Generation Biofuels, a biofuel technology company, as well as its CFO. While at New Generation, Claiborne organised and led the company’s finance and administrative functions, including treasury, human resources (HR), business development, legal, strategic planning, intellectual property and IT.

Prior to joining New Generation in 2007, Claiborne had been CFO of Osiris Therapeutics, a stem cell therapeutics company, since 2004. During his tenure there, he led that company through its initial public offering (IPO) of shares, transforming it from a privately held company to one listed on Nasdaq, which included developing and implementing corporate governance policies and procedures, an SEC financial reporting process and working capital/cost control procedures.

Claiborne began his career at General Electric (GE) in 1982, and held a series of progressively more responsible positions in financial management and senior management, including president and CEO of new enterprise wholesale services at GE Capital.

Claiborne joined MCI Corporation where he was vice president-financial planning and analysis in 1997, and The Home Depot, where he was vice president-financial planning and analysis in 2000. Claiborne graduated from Rutgers University where he earned a BA, Business Administration and an MBA in Finance, from Villanova University.


Related reading